glp 1 compound ending New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our GLP-1 Compounding: When Innovation May

MIC injections vs

1013 Its antimelanogenic properties result from a variety of mechanisms including stimulation of pheomelanin synthesis rather than darker eumelanin, its antioxidant effects, 14 and interference with intracellular trafficking of melanogenic enzymes

If ongoing trials continue to deliver positive results, triple agonist therapies for diabetes may represent the next major evolution in treating obesity, type 2 diabetes, and related metabolic diseases

Restoring gut barrier integrity addresses one of the root drivers of autoimmune inflammation, not just the symptoms

Both are healing peptides, but they work through different mechanisms